CRDL - CBD To Treat Heart Failure? New Study Shows Its Cardioprotective Effects | Benzinga
On Tuesday, Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) announced positive study results demonstrating that subcutaneously administered cannabidiol - the active pharmaceutical ingredient in Cardiol's novel CRD-38 subcutaneous (SUBQ) formulation - slowed increases in body weight and heart weight, and prevented increases in key cardiac inflammatory and remodeling markers in a model of heart failure with preserved ejection fraction (HFpEF).
The study was presented by researchers from Tecnológico de Monterrey, Mexico, one of its international collaborating research centers, at the Heart Failure Society of America Annual Scientific Meeting 2023.
The new findings expand the understanding of the cardioprotective effects of CRD-38 and suggest new therapeutic potential in HFpEF, ...